期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 70, 期 25, 页码 3127-3136出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.10.060
关键词
high-risk patients; self-expanding valve; transcatheter aortic valve replacement
资金
- Edwards Lifesciences
- Symetis
- Abbott Vascular
- Medtronic
- Boston Scientific
- St. Jude Medical
- Biotronik
- Bracco Pharmaceutical
- Terumo
BACKGROUND The CENTERA transcatheter heart valve (THV) is a low-profile, self-expanding nitinol valve made from bovine pericardial tissue that is 14-F compatible with a motorized delivery system allowing for repositionability. OBJECTIVES The pivotal study evaluated safety and efficacy of this THV in high-surgical-risk study patients with severe symptomatic aortic stenosis. METHODS Implantations were completed in 23 centers. Clinical and echocardiographic outcomes were assessed at baseline, discharge, and 30 days. Major events were adjudicated by an independent clinical events committee. Echocardiograms and computed tomography scans were reviewed by core laboratories. The primary endpoint was all-cause mortality at 30 days. RESULTS Between March 25, 2015 and July 5, 2016, 203 patients with severe symptomatic aortic stenosis and increased surgical risk, as determined by the heart team, were treated by transfemoral THV implantation (age 82.7 +/- 5.5 years, 67.5% female, 68.0% New York Heart Association functional class III/IV). At 30 days, mortality was 1%, disabling stroke occurred in 2.5% of patients, and New York Heart Association functional class I/II was observed in 93.0% of patients. Effective orifice area increased from 0.71 +/- 0.20 cm(2) to 1.88 +/- 0.43 cm(2) (p < 0.001). Mean aortic transvalvular gradient decreased from 40.5 +/- 13.2 mm Hg to 7.2 +/- 2.8 mm Hg at 30 days post-procedure (p < 0.001). Paravalvular aortic regurgitation at 30 days was moderate or higher in 0.6% of patients. A new permanent pacemaker was implanted in 4.5% of patients receiving the THV (4.9% for patients at risk). CONCLUSIONS The herein described THV is safe and effective at 30 days with low mortality, significant improvements in hemodynamic outcomes, and low incidence of adverse events. Of particular interest is the low incidence of permanent pacemaker implantations. (Safety and Performance Study of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve [CENTERA-2]; NCT02458560) (J Am Coll Cardiol 2017; 70: 3127-36) (c) 2017 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据